Close Menu

NEW YORK ─ Biotherapeutics and reagents developer Avacta said on Thursday that it has appointed BBI Solutions to manufacture a saliva-based rapid SARS-CoV-2 antigen test that Avacta is developing with Cytiva.

Wetherby, UK-based Avacta said the manufacturing agreement with BBI aims to accelerate the development and validation of a scaled-up manufacturing process with the potential to enable the production of millions of tests per month.

Avacta said it plans to begin clinical validation soon, using the first pilot batches generated as part of a technology transfer process.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.